Integra Lifesciences(DE:IL3)
€12.60+0.70 (+0.80%)
DE:IL3
Integra Lifesciences financials statements
€12.60
At close:+0.70 (+0.80%)
Integra Lifesciences (IL3) Ratios
0 Followers
Integra Lifesciences Ratios
DE:IL3's free cash flow for Q3 2026 was $85.73M. For the 2026 fiscal year, DE:IL3's free cash flow was decreased by $-10.25M and operating cash flow was $95.98M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.54 | 1.17 | 3.45 | 3.62 | 3.39 |
| Quick Ratio | 1.46 | 0.71 | 2.18 | 2.61 | 2.46 |
| Cash Ratio | 0.52 | 0.27 | 0.90 | 1.42 | 1.51 |
| Solvency Ratio | -0.14 | 0.05 | 0.09 | 0.14 | 0.14 |
| Operating Cash Flow Ratio | 0.11 | 0.14 | 0.46 | 0.82 | 0.92 |
| Short-Term Operating Cash Flow Coverage | 0.40 | 0.21 | 9.63 | 5.01 | 5.23 |
| Net Current Asset Value | $ -1.40B | $ -1.41B | $ -1.14B | $ -923.86M | $ -943.86M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.56 | 0.49 | 0.44 | 0.42 | 0.44 |
| Debt-to-Equity Ratio | 1.95 | 1.28 | 1.06 | 0.90 | 0.99 |
| Debt-to-Capital Ratio | 0.66 | 0.56 | 0.51 | 0.47 | 0.50 |
| Long-Term Debt-to-Capital Ratio | 0.62 | 0.44 | 0.48 | 0.44 | 0.47 |
| Financial Leverage Ratio | 3.45 | 2.61 | 2.38 | 2.16 | 2.24 |
| Debt Service Coverage Ratio | -1.31 | 0.30 | 3.68 | 3.43 | 2.91 |
| Interest Coverage Ratio | 0.79 | 0.40 | 2.17 | 4.82 | 3.91 |
| Debt to Market Cap | 1.95 | 1.03 | 0.44 | 0.31 | 0.28 |
| Interest Debt Per Share | 27.61 | 26.69 | 22.17 | 20.24 | 20.27 |
| Net Debt to EBITDA | -5.53 | 8.99 | 5.49 | 3.05 | 3.15 |
| Profitability Margins | |||||
| Gross Profit Margin | 51.69% | 54.77% | 57.39% | 62.29% | 61.24% |
| EBIT Margin | -29.19% | 3.25% | 8.59% | 16.92% | 15.73% |
| EBITDA Margin | -19.90% | 12.00% | 16.60% | 24.69% | 23.75% |
| Operating Profit Margin | 4.18% | 1.76% | 7.23% | 15.34% | 12.79% |
| Pretax Profit Margin | -34.46% | -1.13% | 5.26% | 13.73% | 13.92% |
| Net Profit Margin | -31.58% | -0.43% | 4.39% | 11.59% | 10.96% |
| Continuous Operations Profit Margin | -31.58% | -0.43% | 4.39% | 11.59% | 10.96% |
| Net Income Per EBT | 91.65% | 38.08% | 83.56% | 84.41% | 78.76% |
| EBT Per EBIT | -824.82% | -64.19% | 72.69% | 89.53% | 108.85% |
| Return on Assets (ROA) | -14.34% | -0.17% | 1.79% | 4.64% | 4.47% |
| Return on Equity (ROE) | -49.50% | -0.45% | 4.27% | 10.01% | 10.04% |
| Return on Capital Employed (ROCE) | 2.17% | 0.91% | 3.21% | 6.69% | 5.73% |
| Return on Invested Capital (ROIC) | 1.91% | 0.29% | 2.66% | 5.55% | 4.42% |
| Return on Tangible Assets | -27.88% | -0.40% | 4.08% | 10.47% | 10.42% |
| Earnings Yield | -54.18% | -0.40% | 1.99% | 3.88% | 2.98% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.86 | 5.91 | 5.94 | 5.91 | 6.65 |
| Payables Turnover | 8.25 | 8.83 | 7.11 | 5.75 | 9.67 |
| Inventory Turnover | 1.60 | 1.70 | 1.69 | 1.81 | 1.88 |
| Fixed Asset Turnover | 2.80 | 2.93 | 3.11 | 3.39 | 3.89 |
| Asset Turnover | 0.45 | 0.40 | 0.41 | 0.40 | 0.41 |
| Working Capital Turnover Ratio | 3.79 | 3.54 | 1.94 | 1.88 | 1.87 |
| Cash Conversion Cycle | 245.67 | 235.39 | 226.60 | 199.99 | 210.89 |
| Days of Sales Outstanding | 62.24 | 61.73 | 61.40 | 61.74 | 54.86 |
| Days of Inventory Outstanding | 227.65 | 215.00 | 216.50 | 201.71 | 193.78 |
| Days of Payables Outstanding | 44.23 | 41.34 | 51.30 | 63.45 | 37.76 |
| Operating Cycle | 289.89 | 276.73 | 277.90 | 263.44 | 248.64 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.66 | 1.68 | 1.79 | 3.19 | 3.69 |
| Free Cash Flow Per Share | -0.59 | 0.32 | 0.94 | 2.62 | 3.12 |
| Dividend Paid and CapEx Coverage Ratio | 0.53 | 1.24 | 2.09 | 5.62 | 6.50 |
| Capital Expenditure Coverage Ratio | 0.53 | 1.24 | 2.09 | 5.62 | 6.50 |
| Operating Cash Flow Coverage Ratio | 0.02 | 0.07 | 0.08 | 0.16 | 0.19 |
| Operating Cash Flow to Sales Ratio | 0.03 | 0.08 | 0.09 | 0.17 | 0.20 |
| Free Cash Flow Yield | -4.75% | 1.43% | 2.15% | 4.67% | 4.66% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.85 | -251.44 | 50.25 | 25.77 | 33.56 |
| Price-to-Sales (P/S) Ratio | 0.58 | 1.08 | 2.21 | 2.99 | 3.68 |
| Price-to-Book (P/B) Ratio | 0.91 | 1.13 | 2.14 | 2.58 | 3.37 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -21.06 | 69.96 | 46.58 | 21.41 | 21.46 |
| Price-to-Operating Cash Flow Ratio | 18.92 | 13.50 | 24.32 | 17.60 | 18.16 |
| Price-to-Earnings Growth (PEG) Ratio | -0.00 | 2.28 | -0.84 | 2.86 | 1.26 |
| Enterprise Value Multiple | -8.46 | 18.03 | 18.79 | 15.15 | 18.63 |
| Enterprise Value | 2.75B | 3.48B | 4.81B | 5.83B | 6.83B |
| EV to EBITDA | -8.46 | 18.03 | 18.79 | 15.15 | 18.63 |
| EV to Sales | 1.68 | 2.16 | 3.12 | 3.74 | 4.43 |
| EV to Free Cash Flow | -60.80 | 139.59 | 65.80 | 26.80 | 25.82 |
| EV to Operating Cash Flow | 54.61 | 26.93 | 34.36 | 22.03 | 21.85 |
| Tangible Book Value Per Share | -9.20 | -9.86 | -6.85 | -4.35 | -5.60 |
| Shareholders’ Equity Per Share | 13.60 | 20.07 | 20.31 | 21.74 | 19.89 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.08 | 0.62 | 0.16 | 0.16 | 0.21 |
| Revenue Per Share | 21.31 | 20.91 | 19.72 | 18.77 | 18.21 |
| Net Income Per Share | -6.73 | -0.09 | 0.87 | 2.18 | 2.00 |
| Tax Burden | 0.92 | 0.38 | 0.84 | 0.84 | 0.79 |
| Interest Burden | 1.18 | -0.35 | 0.61 | 0.81 | 0.88 |
| Research & Development to Revenue | 0.06 | 0.07 | 0.07 | 0.06 | 0.06 |
| SG&A to Revenue | 0.43 | 0.45 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.01 | 0.02 | 0.01 | 0.02 | 0.02 |
| Income Quality | -0.10 | -18.63 | 2.07 | 1.46 | 1.85 |
Currency in USD
